LT3661510T - Elgesio pakitimų gydymo būdai - Google Patents

Elgesio pakitimų gydymo būdai

Info

Publication number
LT3661510T
LT3661510T LTEPPCT/EP2018/071120T LTEP2018071120T LT3661510T LT 3661510 T LT3661510 T LT 3661510T LT EP2018071120 T LTEP2018071120 T LT EP2018071120T LT 3661510 T LT3661510 T LT 3661510T
Authority
LT
Lithuania
Prior art keywords
methods
behavior alterations
treating behavior
treating
alterations
Prior art date
Application number
LTEPPCT/EP2018/071120T
Other languages
English (en)
Inventor
Tamara Maes
David ROTLLANT POZO
Christian GRIÑÁN FERRE
Mercè PALLÀS LLIBERIA
Roser NADAL ALEMANY
Antonio ARMARIO GARCÍA
Original Assignee
Oryzon Genomics, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics, S.A. filed Critical Oryzon Genomics, S.A.
Publication of LT3661510T publication Critical patent/LT3661510T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
LTEPPCT/EP2018/071120T 2017-08-03 2018-08-03 Elgesio pakitimų gydymo būdai LT3661510T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17382545 2017-08-03
EP17382544 2017-08-03
EP18382299 2018-04-30
PCT/EP2018/071120 WO2019025588A1 (en) 2017-08-03 2018-08-03 METHODS OF TREATING ALTERATIONS IN BEHAVIOR

Publications (1)

Publication Number Publication Date
LT3661510T true LT3661510T (lt) 2025-01-27

Family

ID=63077881

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/071120T LT3661510T (lt) 2017-08-03 2018-08-03 Elgesio pakitimų gydymo būdai

Country Status (23)

Country Link
US (2) US20200323828A1 (lt)
EP (2) EP4512473A3 (lt)
JP (2) JP2020529995A (lt)
KR (2) KR102685898B1 (lt)
CN (1) CN110996949A (lt)
AU (2) AU2018309372B2 (lt)
BR (1) BR112020000827A2 (lt)
CA (1) CA3071804A1 (lt)
DK (1) DK3661510T3 (lt)
ES (1) ES3001085T3 (lt)
FI (1) FI3661510T3 (lt)
HR (1) HRP20241716T1 (lt)
HU (1) HUE069697T2 (lt)
IL (1) IL272092B2 (lt)
LT (1) LT3661510T (lt)
MX (2) MX2020001323A (lt)
MY (1) MY204406A (lt)
PH (1) PH12020500211A1 (lt)
PL (1) PL3661510T3 (lt)
RS (1) RS66336B1 (lt)
SG (1) SG11202000077RA (lt)
SI (1) SI3661510T1 (lt)
WO (1) WO2019025588A1 (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913290QA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
CN121370879A (zh) * 2019-03-20 2026-01-23 奥莱松基因组股份有限公司 治疗边缘型人格障碍的方法
EP3941465B1 (en) * 2019-03-20 2025-09-17 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
MX2022002420A (es) * 2019-09-03 2022-05-06 Oryzon Genomics Sa Metodos de tratamiento de trastorno de espectro autista.
CN114502561B (zh) * 2019-09-29 2023-12-26 南昌弘益药业有限公司 Lsd1抑制剂
CN118604352B (zh) * 2024-05-22 2025-08-01 暨南大学 Vps13a表达促进剂在制备用于抑郁症诊断和治疗药物中的应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2007021839A2 (en) 2005-08-10 2007-02-22 Johns Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
EP2142287A4 (en) 2007-04-13 2012-05-23 Univ Johns Hopkins INHIBITORS OF LYSINPECIFIC DEMETHYLASE
EP2361242B1 (en) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
WO2010143582A1 (ja) 2009-06-11 2010-12-16 公立大学法人名古屋市立大学 フェニルシクロプロピルアミン誘導体及びlsd1阻害剤
US9708255B2 (en) 2009-08-18 2017-07-18 Robert A. Casero (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
JP5699152B2 (ja) 2009-09-25 2015-04-08 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． リジン特異的デメチラーゼ−１阻害剤およびその使用
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011131697A1 (en) 2010-04-19 2011-10-27 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
CN102985402B (zh) 2010-04-20 2015-04-29 罗马大学 反苯环丙胺衍生物作为组蛋白去甲基酶lsd1和/或lsd2的抑制剂
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
EP3375775A1 (en) 2010-07-29 2018-09-19 Oryzon Genomics, S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US9527805B2 (en) 2010-09-10 2016-12-27 Robert A. Casero Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
PE20141322A1 (es) 2011-03-25 2014-10-05 Glaxosmithkline Intellectual Property (N 2) Limited Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina
GEP201606559B (en) 2011-08-09 2016-10-25 Takeda Pharmaceuticals Co Cyclopropaneamine compound
SG2014009609A (en) 2011-08-15 2014-05-29 Univ Utah Res Found Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors
WO2013033688A1 (en) 2011-09-01 2013-03-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
EP3736265A1 (en) 2011-10-20 2020-11-11 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
EP2776394B1 (en) 2011-10-20 2018-12-26 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
CN105051005B (zh) 2012-10-12 2017-06-13 武田药品工业株式会社 环丙胺化合物及其用途
US9388123B2 (en) 2012-11-28 2016-07-12 Kyoto University LSD1-selective inhibitor having lysine structure
CA2892375A1 (en) 2012-11-30 2014-06-05 Darlene E. MCCORD Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN103054869A (zh) 2013-01-18 2013-04-24 郑州大学 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
WO2014164867A1 (en) 2013-03-11 2014-10-09 Imago Biosciences Kdm1a inhibitors for the treatment of disease
SG11201510376QA (en) 2013-06-19 2016-01-28 Univ Utah Res Found Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
CN103319466B (zh) 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用
BR112016002496B1 (pt) 2013-08-06 2022-07-12 Imago Biosciences Inc. Composto e composição farmacêutica
US9186391B2 (en) 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
US9556170B2 (en) 2013-08-30 2017-01-31 University Of Utah Research Foundation Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors
SMT202300014T1 (it) 2013-12-11 2023-05-12 Celgene Quanticel Research Inc Inibitori della demetilasi lisina-specifica-1
EP3102034A4 (en) 2014-02-07 2017-07-12 MUSC Foundation For Research Development Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CR20160395A (es) 2014-02-13 2016-12-20 Incyte Corp Ciclopropilaminas como inhibidores de lsd1
MY183499A (en) 2014-02-13 2021-02-22 Incyte Corp Cyclopropylamines as lsd1 inhibitors
CN106458856A (zh) 2014-03-07 2017-02-22 约翰霍普金斯大学 组蛋白赖氨酸特异性的脱甲基酶(lsd1)和组蛋白脱乙酰基酶(hdac)的抑制剂
CN103893163B (zh) 2014-03-28 2016-02-03 中国药科大学 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用
NZ725262A (en) 2014-04-11 2023-01-27 Takeda Pharmaceuticals Co Cyclopropanamine compound and use thereof
CN103961340B (zh) 2014-04-30 2019-06-25 南通中国科学院海洋研究所海洋科学与技术研究发展中心 一类lsd1抑制剂及其应用
AU2015253040B2 (en) 2014-05-01 2020-04-09 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
EP3148974B1 (en) 2014-05-30 2018-09-26 Istituto Europeo di Oncologia S.r.l. Cyclopropylamine compounds as histone demethylase inhibitors
HUE050564T2 (hu) 2014-06-27 2020-12-28 Celgene Quanticel Res Inc Lizinspecifikus demetiláz-1 inhibitorai
CN104119280B (zh) 2014-06-27 2016-03-16 郑州大学 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用
SG11201700007YA (en) 2014-07-03 2017-01-27 Celgene Quanticel Res Inc Inhibitors of lysine specific demethylase-1
SI3511319T1 (sl) 2014-07-03 2023-10-30 Celgene Quanticel Research, Inc. Inhibitorji lizin specifične demetilaze-1
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
BR112017004334A2 (pt) 2014-09-05 2018-08-07 Celgene Quanticel Res Inc inibidores de desmetilase específica de lisina-1.
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
WO2016123387A1 (en) 2015-01-30 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
PT3256218T (pt) 2015-02-12 2025-01-29 Imago Biosciences Inc Um inibidor de kdm1a e a sua utilização na terapia
CN106146361A (zh) 2015-03-16 2016-11-23 四川大学 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途
MA51438A (fr) 2015-04-03 2021-04-14 Incyte Corp Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
CN106045862B (zh) 2015-04-10 2019-04-23 上海迪诺医药科技有限公司 环丙胺类螺(杂)环化合物、其药物组合物及应用
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
WO2017004519A1 (en) 2015-07-02 2017-01-05 University Of Utah Research Foundation Substituted benzohydrazide analogs as histone demethylase inhibitors
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
HRP20210144T8 (hr) 2015-11-05 2021-04-16 Celgene Quanticel Research, Inc. Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primjena u liječenju raka
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
SG11201804121RA (en) 2015-11-27 2018-06-28 Taiho Pharmaceutical Co Ltd Novel biphenyl compound or salt thereof
WO2017109061A1 (en) 2015-12-23 2017-06-29 Ieo - Istituto Europeo Di Oncologia S.R.L. Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN108884029B (zh) 2015-12-29 2021-10-26 米拉蒂医疗股份有限公司 Lsd1抑制剂
WO2017114497A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
ES2831832T3 (es) 2016-03-01 2021-06-09 Novartis Ag Compuestos de indol ciano-sustituidos y usos de los mismos como inhibidores de LSD1
CN107200706A (zh) 2016-03-16 2017-09-26 中国科学院上海药物研究所 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
US20170283397A1 (en) 2016-03-31 2017-10-05 University Of Utah Research Foundation Substituted 1-h-indol-3-yl-benzamide and 1, 1'-biphenyl analogs as histone demethylase inhibitors
CN109153636B (zh) 2016-05-09 2021-10-22 朱比连特埃皮科尔有限责任公司 作为双重lsd1/hdac抑制剂的环丙基-酰胺化合物
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
CN107513068A (zh) 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
CN106478639B (zh) 2016-09-05 2018-09-18 郑州大学 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用
CN106432248B (zh) 2016-09-27 2018-11-27 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
WO2018081342A1 (en) 2016-10-26 2018-05-03 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
PT3532459T (pt) 2016-10-26 2023-11-10 Constellation Pharmaceuticals Inc Inibidores de lsd1 e seus usos médicos
CN106831489B (zh) 2017-03-23 2018-04-17 郑州大学 苯环丙胺酰腙类化合物、制备方法及其应用
CN106928235A (zh) 2017-05-03 2017-07-07 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用

Also Published As

Publication number Publication date
JP2023159354A (ja) 2023-10-31
IL272092B1 (en) 2025-09-01
KR102685898B1 (ko) 2024-07-19
RS66336B1 (sr) 2025-01-31
EP4512473A3 (en) 2025-05-14
IL272092A (en) 2020-03-31
SI3661510T1 (sl) 2025-03-31
FI3661510T3 (fi) 2024-12-18
US20200323828A1 (en) 2020-10-15
ES3001085T3 (es) 2025-03-04
EP4512473A2 (en) 2025-02-26
CA3071804A1 (en) 2019-02-07
AU2018309372A1 (en) 2020-01-30
AU2018309372B2 (en) 2024-08-15
MY204406A (en) 2024-08-27
HUE069697T2 (hu) 2025-04-28
EP3661510A1 (en) 2020-06-10
AU2024264660A1 (en) 2024-12-05
PL3661510T3 (pl) 2025-04-14
US20240277673A1 (en) 2024-08-22
RU2020109167A (ru) 2021-09-03
IL272092B2 (en) 2026-01-01
RU2020109167A3 (lt) 2022-02-10
KR20240122847A (ko) 2024-08-13
KR20200036920A (ko) 2020-04-07
SG11202000077RA (en) 2020-02-27
HRP20241716T1 (hr) 2025-02-14
PH12020500211A1 (en) 2020-10-19
MX2020001323A (es) 2020-03-20
WO2019025588A1 (en) 2019-02-07
EP3661510B1 (en) 2024-10-09
BR112020000827A2 (pt) 2020-07-21
CN110996949A (zh) 2020-04-10
DK3661510T3 (da) 2025-01-02
JP2020529995A (ja) 2020-10-15
MX2023009388A (es) 2023-08-23
KR102912513B1 (ko) 2026-01-15

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL266770A (en) Methods for treating inflammatory conditions
SG10202110594UA (en) Methods of treating tumor
IL260199B (en) Cancer treatment methods
IL255189A0 (en) Cancer treatment methods
IL252296A0 (en) Methods for treating multiple sclerosis
ZA201903873B (en) Methods of treating cochlear synaptopathy
IL267199A (en) A method for treating epilepsy
IL256207B (en) Methods for treating multiple sclerosis
SI3661510T1 (sl) Postopki zdravljenja vedenjskih sprememb
IL290069A (en) Methods for treating eye conditions
SG11201706693QA (en) Methods of treating infertility
EP3684342C0 (en) TREATMENT PROCEDURES
ZA201705877B (en) Method of treating diseases
IL256109A (en) Methods for the treatment or prevention of protopathy
GB201706406D0 (en) Method of treatment
GB201815588D0 (en) Method of treatment
PL3220952T3 (pl) Sposób leczenia lub zapobiegania udarowi
IL253847A0 (en) Methods of treating diseases
ZA201906319B (en) Methods of treating depression
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201602802D0 (en) Method of treatment
SG11201710199PA (en) Methods of treating multiple sclerosis
PT3661510T (pt) Métodos de tratamento de alterações do comportamento